{"success":true,"data":{"pressRelease":{"id":"109967","rtpr_id":"nGNX5NThJ6","ticker":"SPRO","exchange":"NASDAQ","all_tickers":["SPRO"],"title":"Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","author":"Globe Newswire","published_at":"2026-08-05T20:05:00.352Z","article_body":"CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.\n(https://www.globenewswire.com/Tracker?data=_eXou-WgTV25btHmxKbookNa8sXjihlHoJultCdSgzBYV9JU4WHxqJu5XzN6hizwX52iPLuJTl-4BNBd-ETuVaLZOzUOHjIrZ0IlheL8d-E=)\n(Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on\nadvancing next-generation medicines in immunology and inflammation, today\nannounced that on July 22, 2026, the Compensation Committee of Spero’s Board\nof Directors approved a grant, to be made on August 3(rd), of an aggregate of\n324,622 stock options and 162,311 restricted stock unit awards (RSUs) to a new\nemployee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive\nPlan, as amended (2019 Inducement Plan). The stock options and RSUs are being\ngranted as an inducement material to Spero’s new employee in accordance with\nNasdaq Listing Rule 5635(c)(4).\n\nThe 2019 Inducement Plan is used exclusively for the grant of equity awards to\nindividuals who were not previously employees of Spero (or following a bona\nfide period of non-employment), as a material inducement for such individuals\nentering into employment with Spero, pursuant to Rule 5635(c)(4) of the Nasdaq\nListing Rules.\n\nThe shares underlying the option vest as to 25% on August 3, 2027, with the\nremainder vesting in 36 equal monthly installments thereafter, subject to the\nemployee’s continued employment with Spero through the applicable vesting\ndates. The RSUs will vest in four equal annual installments beginning on\nAugust 3, 2027, subject to the employees‘ continued employment with Spero\nthrough the applicable vesting dates. The stock options and the RSUs are\nsubject to the terms and conditions of the 2019 Inducement Plan and the stock\noption and the RSU agreement covering the grant.\n\nAbout Spero Therapeutics\nSpero Therapeutics is a clinical-stage biopharmaceutical company focused on\nadvancing next-generation medicines for patients with serious immune-mediated\ndiseases. The company’s lead program, SP001, is a third-generation,\nFc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related\ndisease, with potential for development in additional immunological &\ninflammatory diseases. For more information, visit www.sperotx.com\n\nInvestor Relations Contact:\nShai Biran, PhD\nSpero Therapeutics \nIR@Sperotherapeutics.com \n\n(https://www.globenewswire.com/Tracker?data=eg5bS0FUBmoqCvPTS6U3RRknfFrSvWRMNTPuToNqz5sllEdIw79qE6rZJHhDoPj4iHjFk9N-ZokvCwdb03elZQ==)\n\nMedia Inquiries: media@sperotherapeutics.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/908599b7-dec6-4771-91e4-e8e60bea78e6)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX5NThJ6","title":"Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","author":"Globe Newswire","ticker":"SPRO","created":"2026-08-05T20:05:00.352Z","tickers":["SPRO"],"exchange":"NASDAQ","article_body":"CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.\n(https://www.globenewswire.com/Tracker?data=_eXou-WgTV25btHmxKbookNa8sXjihlHoJultCdSgzBYV9JU4WHxqJu5XzN6hizwX52iPLuJTl-4BNBd-ETuVaLZOzUOHjIrZ0IlheL8d-E=)\n(Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on\nadvancing next-generation medicines in immunology and inflammation, today\nannounced that on July 22, 2026, the Compensation Committee of Spero’s Board\nof Directors approved a grant, to be made on August 3(rd), of an aggregate of\n324,622 stock options and 162,311 restricted stock unit awards (RSUs) to a new\nemployee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive\nPlan, as amended (2019 Inducement Plan). The stock options and RSUs are being\ngranted as an inducement material to Spero’s new employee in accordance with\nNasdaq Listing Rule 5635(c)(4).\n\nThe 2019 Inducement Plan is used exclusively for the grant of equity awards to\nindividuals who were not previously employees of Spero (or following a bona\nfide period of non-employment), as a material inducement for such individuals\nentering into employment with Spero, pursuant to Rule 5635(c)(4) of the Nasdaq\nListing Rules.\n\nThe shares underlying the option vest as to 25% on August 3, 2027, with the\nremainder vesting in 36 equal monthly installments thereafter, subject to the\nemployee’s continued employment with Spero through the applicable vesting\ndates. The RSUs will vest in four equal annual installments beginning on\nAugust 3, 2027, subject to the employees‘ continued employment with Spero\nthrough the applicable vesting dates. The stock options and the RSUs are\nsubject to the terms and conditions of the 2019 Inducement Plan and the stock\noption and the RSU agreement covering the grant.\n\nAbout Spero Therapeutics\nSpero Therapeutics is a clinical-stage biopharmaceutical company focused on\nadvancing next-generation medicines for patients with serious immune-mediated\ndiseases. The company’s lead program, SP001, is a third-generation,\nFc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related\ndisease, with potential for development in additional immunological &\ninflammatory diseases. For more information, visit www.sperotx.com\n\nInvestor Relations Contact:\nShai Biran, PhD\nSpero Therapeutics \nIR@Sperotherapeutics.com \n\n(https://www.globenewswire.com/Tracker?data=eg5bS0FUBmoqCvPTS6U3RRknfFrSvWRMNTPuToNqz5sllEdIw79qE6rZJHhDoPj4iHjFk9N-ZokvCwdb03elZQ==)\n\nMedia Inquiries: media@sperotherapeutics.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/908599b7-dec6-4771-91e4-e8e60bea78e6)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-05T20:05:00.40802894Z","server_sent_at_ms":1785960300408},"received_at":"2026-08-05T20:05:00.531Z","source_url":"https://www.globenewswire.com/news-release/2026/08/05/3339713/0/en/spero-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html"},"analysis":{"id":"98970","press_release_id":"109967","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Spero Therapeutics granted 324,622 stock options and 162,311 restricted stock units to a new employee under its 2019 Inducement Equity Incentive Plan.\n\nThe awards were approved by the Compensation Committee on July 22, 2026, and granted on August 3, 2026, as an inducement material to the individual entering into employment.\n\nOptions vest 25% on August 3, 2027, with the remainder vesting monthly over 36 months, while RSUs vest in four equal annual installments beginning August 3, 2027.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine inducement grant for new hire."},"keyFigures":{"customDimensions":{"rsus_granted":162311,"options_granted":324622}},"quotedText":"","namedEntities":{"people":[{"name":"Shai Biran, PhD","role":"Investor Relations Contact"}],"products":["SP001"],"companies":[{"name":"Spero Therapeutics, Inc.","ticker":"SPRO"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine inducement grant to an unnamed new employee; standard corporate governance disclosure with no material business impact."},"tickerRelevance":{"others":[],"primary":"SPRO"},"globalImportance":5,"audienceRelevance":5,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small_cap","eventGravity":"routine_corporate_governance"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Spero Therapeutics granted 324,622 stock options and 162,311 restricted stock units to a new employee under its 2019 Inducement Equity Incentive Plan.\n\nThe awards were approved by the Compensation Committee on July 22, 2026, and granted on August 3, 2026, as an inducement material to the individual entering into employment.\n\nOptions vest 25% on August 3, 2027, with the remainder vesting monthly over 36 months, while RSUs vest in four equal annual installments beginning August 3, 2027.","key_figures":{"customDimensions":{"rsus_granted":162311,"options_granted":324622}},"named_entities":{"people":[{"name":"Shai Biran, PhD","role":"Investor Relations Contact"}],"products":["SP001"],"companies":[{"name":"Spero Therapeutics, Inc.","ticker":"SPRO"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-05T23:13:17.791Z","global_importance":5,"audience_relevance":5,"importance_components":{"tickerTier":"small_cap","eventGravity":"routine_corporate_governance"}},"durationMs":101456,"modelName":"glm-4.7"}}